Neuroscience for addiction medicine: from prevention to rehabilitation - constructs and drugs
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Amsterdam ; Boston ; Heidelberg ; London ; New York ; Oxford ; Paris ; San Diego ; San Francisco ; Singapore ; Sydney ; Tokyo
Elsevier
2016
|
| Ausgabe: | First edition |
| Schriftenreihe: | Progress in brain research
volume 223 |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | xx, 357 Seiten Illustrationen 24 cm |
| ISBN: | 9780444635457 0444635459 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV043593032 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 160609s2016 a||| |||| 00||| eng d | ||
| 016 | 7 | |a 847038289 |2 DE-101 | |
| 020 | |a 9780444635457 |c hbk. |9 978-0-444-63545-7 | ||
| 020 | |a 0444635459 |c hbk. |9 0-444-63545-9 | ||
| 035 | |a (OCoLC)951551737 | ||
| 035 | |a (DE-599)GBV847038289 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 245 | 1 | 0 | |a Neuroscience for addiction medicine |b from prevention to rehabilitation - constructs and drugs |c edited by Hamed Ekhtiari (Neurocognitive Laboratory, Iranian National Center for Addiction Studies, INCAS ; Research Center for Molecular and Cellular Imaging, RCMCI, Tehran University of Medical Sciences, and Translational Neuroscience Program, Institute for Cognitive Science Studies, ICSS, Tehran, Iran), Martin Paulus (Laureate Institute for Brain Research, LIBR, Tulsa, OK, United States) |
| 250 | |a First edition | ||
| 264 | 1 | |a Amsterdam ; Boston ; Heidelberg ; London ; New York ; Oxford ; Paris ; San Diego ; San Francisco ; Singapore ; Sydney ; Tokyo |b Elsevier |c 2016 | |
| 300 | |a xx, 357 Seiten |b Illustrationen |c 24 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Progress in brain research |v volume 223 | |
| 700 | 1 | |a Ekhtiari, Hamed |d 1978- |0 (DE-588)1103144065 |4 edt | |
| 700 | 1 | |a Paulus, Martin P. |d 1961- |0 (DE-588)1084786982 |4 edt | |
| 830 | 0 | |a Progress in brain research |v volume 223 |w (DE-604)BV008000363 |9 223 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029007373&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029007373 | ||
Datensatz im Suchindex
| _version_ | 1804176331378786304 |
|---|---|
| adam_text | Titel: Neuroscience for addiction medicine
Autor: Ekhtiari, Hamed
Jahr: 2016
Contents
Contributors...............................................................................................................v
Preface...................................................................................................................xxv
PART I NEUROSCIENCE METHODS FOR ADDICTION
_MEDICINE_
CHAPTER 1 Animal Models for Addiction Medicine: From
Vulnerable Phenotypes to Addicted Individuals............3
Michael A. Nader
1. Introduction.....................................................................................3
2. Types of Animal Models................................................................4
2.1. Unconditioned Behaviors.......................................................4
2.2. Conditioned Place Preference................................................7
2.3. Drug Discrimination...............................................................9
2.4. Dmg Self-Administration Models........................................11
3. Conclusions and Future Directions..............................................16
Acknowledgments........................................................................17
References.....................................................................................17
CHAPTER 2 Animal Models of Drug Relapse and Craving:
From Drug Priming-Induced Reinstatement to
Incubation of Craving After Voluntary Abstinence......25
Marco Venniro, Daniele Caprioli, Yavin Shaham
1. Introduction...................................................................................26
2. Extinction-Based Relapse Models................................................29
2.1. Reinstatement........................................................................29
2.2. Reacquisition........................................................................35
2.3. Resurgence............................................................................36
3. Abstinence-Based Relapse Models..............................................37
3.1. Forced Abstinence and Incubation of Drug Craving...........37
3.2. Voluntary Abstinence Induced by Adverse
Consequences of Drug Intake..............................................38
3.3. Voluntary Abstinence Induced by Introducing a
Nondrug Reward in a Choice Procedure.............................39
4. Conclusions...................................................................................40
Acknowledgments........................................................................41
References.....................................................................................41
xiii
xiv Contents
CHAPTER 3 Computational Modeling for Addiction Medicine:
From Cognitive Models to Clinical Applications..........53
Woo Young Ahn, Junyi Dai, Jasmin Vassileva,
Jerome R. Busemeyer, Julie C. Stout
1. IGT and SGT Decision-Making Tasks.........................................54
1.1. The Iowa Gambling Task.....................................................55
1.2. Soochow Gambling Task.....................................................56
2. The EVL and PVL Models...........................................................57
2.1. Model....................................................................................57
2.2. Parameters.............................................................................58
2.3. Estimation Methods..............................................................58
2.4. Model Testing and Comparison...........................................59
2.5. Parameter Consistency.........................................................59
3. Applications of the EVL and PVL Models to
Clinical Populations Including Addiction....................................60
3.1. Early Applications................................................................60
3.2. Recent Applications..............................................................60
3.3. Parameter Consistency.........................................................61
4. Conclusion and Future Directions................................................62
Acknowledgments........................................................................63
References.....................................................................................64
CHAPTER 4 Electrophysiology for Addiction Medicine:
From Methodology to Conceptualization of
Reward Deficits........................................................................67
Jennifer L. Stewart, April C. May
1. Gearing Up: Employing Electrophysiology to Study
Reward in Addiction.....................................................................67
2. What Terrain Have We Covered in the Past Decade?................68
3. Roadmap for Our Journey............................................................68
4. Our Tools: Electrophysiological Markers of Reward..................69
4.1. Error-Related Negativity......................................................70
4.2. Feedback-Related Negativity...............................................70
4.3. N200......................................................................................73
4.4. P300......................................................................................73
4.5. Late Positive Potential..........................................................77
5. Comparing and Contrasting Types of Addiction.........................79
6. Promising Avenues Ahead...........................................................80
References.....................................................................................81
Contents
CHAPTER 5 Neurocognitive Rehabilitation for Addiction
Medicine: From Neurophysiological Markers to
Cognitive Rehabilitation and Relapse Prevention.......85
Salvatore Campanella
1. Introduction...................................................................................86
2. A Possible Role for ERPs.............................................................88
3. Preliminary Evidence from Alcohol Abuse Studies....................89
4. Converging Evidence from Other Addictive States.....................92
5. Conclusion and Future Directions................................................95
Acknowledgments........................................................................98
References.....................................................................................98
CHAPTER 6 Structural Imaging for Addiction Medicine:
From Neurostructure to Neuroplasticity........................105
Gregory G. Brown, Joanna Jacobus, Benjamin McKenna
1. Introduction.................................................................................105
2. Marijuana....................................................................................107
3. Adolescence (Average Sample Age 21).................................107
3.1. Quantitative Morphometry.................................................107
3.2. Diffusion Tensor Imaging..................................................109
4. Adulthood (Average Sample Age 22, on Average)................109
4.1. Quantitative Morphometry.................................................109
4.2. Diffusion Tensor Imaging..................................................114
4.3. Summary.............................................................................114
5. Stimulants....................................................................................115
6. Prenatal Exposure.......................................................................115
6.1. Quantitative Morphometry.................................................115
6.2. Diffusion Tensor Imaging..................................................116
7. Exposure in Adolescence and Adulthood..................................116
7.1. Quantitative Morphometry.................................................116
7.2. Diffusion Tensor Imaging..................................................117
7.3. Summary.............................................................................117
8. Opiates.........................................................................................117
9. Quantitative Morphometry.........................................................118
10. Diffusion Tensor Imaging...........................................................119
10.1. Summary...........................................................................119
11. Treatment Implications...............................................................120
12. Conclusions and Future Directions............................................120
References...................................................................................121
Contents
CHAPTER 7 Functional Neuroimaging for Addiction Medicine:
From Mechanisms to Practical Considerations..........129
Hamed Ekhtiari, Ashkan Faghiri, Mohammad-Ali Oghabian,
Martin P. Paulus
1. Introduction.................................................................................130
2. Main Cognitive Targets in fMRI for Addiction Medicine........130
2.1. Drug Cue Reactivity (Positive Reinforcement).................131
2.2. Stress/Emotion Reactivity (Negative Reinforcement).......133
2.3. Decision Making.................................................................133
2.4. Executive Control...............................................................133
2.5. Other Processes Associated with Addictive Behaviors.....134
2.6. General Cognitive Impairments.........................................134
3. Resting-State fMRI for Addiction Medicine..............................136
4. fMRI Studies in Addiction Populations.....................................136
4.1. Mapping Studies.................................................................136
4.2. Prediction (Risk) Studies....................................................143
4.3. Longitudinal (Follow-Up) Studies.....................................143
4.4. Neurofeedback Studies.......................................................144
5. Possible Applications of fMRI for Addiction Medicine............144
5.1. Prediction............................................................................144
5.2. Measuring and Monitoring.................................................145
5.3. Planning..............................................................................145
5.4. Integrating...........................................................................146
5.5. Advocacy and Awareness...................................................146
6. Major Challenges to fMRI for Addiction Medicine..................147
6.1. Extending Power of fMRI Evidences................................147
6.2. Moving from Group Data and Measures to
Individualized Decisions....................................................148
6.3. Defining the fMRI Costs and Benefits in Comparison
to Other Tools.....................................................................148
7. Conclusion and Future Directions..............................................148
Acknowledgments......................................................................149
References...................................................................................149
CHAPTER 8 Resting State Functional Connectivity Analysis
for Addiction Medicine: From Individual Loci
to Complex Networks...........................................................155
Vani Pariyadath, Joshua L. Gowin, Elliot A. Stein
1. Introduction.................................................................................156
1.1. Mesocorticolimbic Circuits and rsFC................................158
1.2. Corticolimbic Connectivity in Addiction...........................160
Contents xvii
1.3. Striatolimbic Connectivity in Addiction............................162
1.4. Conclusions from Our Review of Mesocorticolimbic
rsFC Studies........................................................................162
1.5. Addiction—Dysfunctional Processing of Negative
Consequences......................................................................164
1.6. The Missing Participant Groups in Addiction Studies......166
1.7. Emerging Tools for rsFC Research....................................167
2. Conclusions and Future Directions............................................168
Acknowledgments......................................................................168
References...................................................................................168
CHAPTER 9 PET Imaging for Addiction Medicine: From
Neural Mechanisms to Clinical Considerations.........175
Corinde E. Wiers, Elizabeth Cabrera, Emily Skarda,
Nora D. Volkow, Gene-Jack Wang
1. Introduction.................................................................................175
2. PET Technologies to Study the Neurobiological
Mechanisms Underlying Addiction............................................176
3. PET Studies on Dopaminergic Neurotransmission
in Addiction................................................................................176
3.1. DA Receptor Availability...................................................177
3.2. DA Release.........................................................................178
3.3. DA Synthesis Capacity.......................................................179
3.4. DAT Availability................................................................180
4. PET Studies in Addiction Beyond DA......................................181
4.1. FDG.....................................................................................181
4.2. PET to Research Neuroinflammatory Processes in
Addiction............................................................................182
4.3. Monoamine Oxidase System..............................................183
4.4. Opioid System....................................................................184
4.5. Serotonin System................................................................185
4.6. Nicotinic System.................................................................186
4.7. Endocannabinoid System...................................................187
4.8. GABAergic System............................................................188
4.9. Norepinephrine System......................................................188
5. Future Directions........................................................................189
5.1. Multimodal Imaging: Interaction Between Different
Modalities...........................................................................189
5.2. Genetics and Epigenetics....................................................190
5.3. Development of New Tracers............................................191
5.4. Medication Development...................................................191
xviii Contents
6. PET, a Diagnostic Instrument?...................................................192
7. Conclusion and Future Directions..............................................193
Acknowledgments......................................................................193
References...................................................................................193
CHAPTER 10 Genetic Imaging Consortium for Addiction
Medicine: From Neuroimaging to Genes......................203
Scott Mackey, Kees-Jan Kan, Bader Chaarani, Nelly Alia-Klein,
Albert Batalla, Samantha Brooks, Janna Cousijn, Alain Dagher,
Michiel de Ruiter, Sylvane Desrivieres, Sarah W. Feldstein Ewing,
Rita Z. Goldstein, Anna E. Goudriaan, Mary M. Heitzeg,
Kent Hutchison, Chiang-Shan R. Li, Edythe D. London,
Valentina Lorenzetti, Maartje Luijten, Rocio Martin-Santos, Reza
Momenan, Angelica M. Morales, Martin P. Paulus, Tomas Paus,
Godfrey Pearlson, Renee Schluter, Lianne Schmaal, Gunter
Schumann, Rajita Sinha, Zsuzsika Sjoerds, Dan J. Stein, Elliot A.
Stein, Nadia Solowij, Susan Tapert, Anne Uhlmann, Dick Veltman,
Ruth van Hoist, Henrik Walter, Margaret J. Wright, Murat Yucel,
Deborah Yurgelun-Todd, Derrek P. Hibar, Neda Jahanshad,
Paul M. Thompson, David C. Glahn, Hugh Garavan, Patricia Conrod
1. Introduction.................................................................................205
2. Genetic Basis of Addiction.........................................................206
2.1. Brain Endophenotypes........................................................206
2.2. Challenges...........................................................................207
3. Enhancing Neuroimaging Genetics Through Meta-analysis.....208
3.1. Disease Working Groups....................................................210
4. ENIGMA Addiction Working Group.........................................210
4.1. Initial Project......................................................................212
5. Summary and Future Directions.................................................213
5.1. Addiction Medicine............................................................214
Acknowledgments......................................................................214
References...................................................................................214
PART II NEUROSCIENCE FOR INTERVENTIONS
_IN ADDICTION MEDICINE_
CHAPTER 11 Human Pharmacology for Addiction Medicine:
From Evidence to Clinical Recommendations.............227
Boris B. Quednow, Marcus Herdener
1. Introduction.................................................................................228
2. Alcohol Use Disorders................................................................228
Contents xix
2.1. Pharmacotherapy of Acute Alcohol Withdrawal...............229
2.2. Reduction of Use and Relapse Prevention in Alcohol
Dependence.........................................................................230
2.3. Pharmacological Treatment Options to Support
Abstinence in Alcohol Dependence...................................231
2.4. Pharmacological Treatment Options to Support
Reduced Drinking...............................................................232
3. Nicotine.......................................................................................233
4. Opioid Use Disorders.................................................................234
4.1. Pharmacotherapy of Opioid Withdrawal...........................235
4.2. Pharmacological Treatment Options to Support
Abstinence in Opioid Dependence.....................................235
4.3. Substitution Therapy for Opioid Dependence...................236
5. Cocaine and Amphetamines.......................................................237
5.1. Withdrawal..........................................................................237
5.2. Reduction of Use and Relapse Prevention.........................238
5.3. Substitution.........................................................................239
6. Cannabis......................................................................................240
7. Benzodiazepines..........................................................................240
8. Gamma-Hydroxybutyrate...........................................................241
9. Conclusion and Future Directions..............................................242
Acknowledgments......................................................................242
References...................................................................................242
CHAPTER 12 Emerging Targets for Addiction
Neuropharmacology: From Mechanisms
to Therapeutics......................................................................251
Massimo Ubaldi, Nazzareno Cannella, Roberto Ciccocioppo
1. Introduction.................................................................................252
2. Peroxisome Proliferating Activator Receptors...........................254
3. cAMP Response Element-Binding Protein and the
Inhibition of Phosphodiesterase Enzymes..................................256
3.1. PDE4...................................................................................258
3.2. PDE10A..............................................................................258
3.3. PDE7...................................................................................259
4. Stress-Related Neuropeptides.....................................................260
4.1. Corticotropin-Releasing Factor..........................................260
4.2. N/OFQ-NOP.......................................................................261
4.3. Hypocretins/Orexins...........................................................263
4.4. Neuropeptide S...................................................................265
4.5. NK1 Receptor.....................................................................266
Contents
5. Conclusion and Future Directions..............................................267
Acknowledgments......................................................................271
References...................................................................................271
CHAPTER 13 Cognitive Interventions for Addiction Medicine:
Understanding the Underlying Neurobiological
Mechanisms............................................................................285
Anna Zilverstand, Muhammad A. Parvaz, Scott J. Moeller,
Rita Z. Goldstein
1. Introduction.................................................................................286
2. Cognitive Interventions...............................................................287
2.1. Cognitive Behavioral Therapy...........................................287
2.2. Cognitive Inhibition............................................................291
2.3. Motivational Interventions.................................................293
2.4. Affect Regulation...............................................................294
2.5. Mindfulness Training.........................................................295
2.6. Neurofeedback Training.....................................................296
3. Summary.....................................................................................298
4. Conclusion and Future Directions..............................................299
Acknowledgments......................................................................300
References...................................................................................300
CHAPTER 14 Adolescent Psychotherapy for Addiction Medicine:
From Brain Development to Neurocognitive
Treatment Mechanisms.......................................................305
Rachel E. Thayer, Sarah W. Feldstein Ewing
1. Overview.....................................................................................306
2. Adolescent Brain Development and Addiction..........................306
2.1. Brain Development in Adolescence...................................306
2.2. Interactions With Substance Use.......................................307
2.3. Potential Regions to Target in Intervention.......................310
3. Neurocognitive Responses to Intervention.................................311
3.1. Contingency Management..................................................311
3.2. Family Therapies................................................................311
3.3. Cue Exposure......................................................................314
3.4. Motivational Interviewing..................................................315
3.5. Cognitive Behavioral Therapy...........................................316
3.6. Mindfulness-Based Interventions.......................................317
4. Conclusions and Future Directions............................................318
References...................................................................................318
Contents
CHAPTER 15 Cognitive Neuroscience of Cognitive Retraining for
Addiction Medicine: From Mediating Mechanisms
to Questions of Efficacy......................................................323
Thomas E. Gladwin, Corinde E. Wiers, Reinout W. Wiers
1. Introduction.................................................................................324
2. Cognitive Bias Modification......................................................326
3. Mechanisms of CBM..................................................................328
4. CBM: (When) Does It Work?....................................................329
5. Developments in Dual-Process Models......................................331
6. Enhancing Efficacy and Efficiency of CBM.............................332
7. Conclusion and Future Directions..............................................333
References...................................................................................335
CHAPTER 16 Perspectives on Neurocognitive Rehabilitation as
an Adjunct Treatment for Addictive Disorders: From
Cognitive Improvement to Relapse Prevention...........345
Tara Rezapour, Elise E. DeVito, Mehmet Sofuoglu,
Hamed Ekhtiari
1. Introduction.................................................................................346
2. Potential Cognitive Targets for Rehabilitation..........................347
2.1. Memory and Learning........................................................347
2.2. Motor Functions..................................................................348
2.3. Social and Emotional Processing.......................................348
2.4. Attention and Working Memory........................................348
2.5. Impulsivity, Inhibition, and Self-Control...........................348
2.6. Other Executive Functions.................................................349
3. Cognitive Rehabilitation Therapy Methods...............................349
3.1. Cognitive Stimulation Therapy..........................................350
3.2. Strategy Training................................................................350
3.3. Meditation, Mindfulness, and Metacognitive Training.....350
3.4. Physical Exercise................................................................350
4. Efficacy of Neurocognitive Rehabilitation in Addiction
Medicine......................................................................................351
5. Methods for Presenting the Rationale of CRT to
Patients with Addictions.............................................................356
5.1. Empowering the Patient and Avoiding the
Damaged Brain Label.....................................................356
5.2. Giving Realistic Hope for Recovery..................................356
5.3. Improving Motivation and Commitment...........................356
5.4. Encourage Healthy Behaviors............................................357
6. Principles of Cognitive Rehabilitation for Drug Addiction.......357
6.1. Integrated Adjunct Therapy................................................357
xxii Contents
6.2. Patient Tailored...................................................................357
6.3. Graded for Intensity Escalation..........................................358
6.4. Treatment Contracts for CRT.............................................358
6.5. Reinforcing Positive Behavior...........................................358
6.6. Metacognition Supported...................................................358
6.7. Real-Life Application.........................................................358
6.8. Engaging Family Members................................................359
7. Challenges of CRT for Addiction..............................................359
7.1. Overall Efficacy of CRT....................................................359
7.2. Screening and Patient Selection.........................................359
7.3. Treatment Adherence.........................................................360
7.4. Parameters of CRT.............................................................360
7.5. Mode of Treatment Delivery..............................................360
7.6. Single Versus. Multiple Cognitive Targets........................361
7.7. Monitoring and Outcome Measures...................................361
7.8. Cost Effectiveness..............................................................361
8. Conclusions and Future Directions............................................361
Acknowledgments......................................................................362
References...................................................................................362
CHAPTER 17 Noninvasive Brain Stimulation for Addiction
Medicine: From Monitoring to Modulation..................371
Fatemeh Yavari, Alireza Shahbabaie, Jorge Leite,
Sandra Carvalho, Hamed Ekhtiari, Felipe Fregni
1. Introduction.................................................................................372
2. NIBS for Neurochemical and Neuroplasticity Assessments......373
3. Using Repetitive NIBS as a Mechanistic and
Therapeutic Tool.........................................................................382
4. NIBS and Clinical Practice in Addiction Medicine:
Limitations, Open Problems, and Future Directions.................387
Acknowledgments......................................................................391
References...................................................................................391
CHAPTER 18 What the Alcohol Doctor Ordered from the
Neuroscientist: Theragnostic Biomarkers for
Personalized Treatments....................................................401
Markus Heilig, Lorenzo Leggio
1. Introduction.................................................................................402
2. Individual Treatment Predictive Biomarkers: Theragnostics ....404
3. Alcohol-Induced Dopamine Activation as a Theragnostic
Biomarker....................................................................................405
4. Measures of Glutamate Activity as Theragnostic
Biomarkers..................................................................................408
5. Conclusions and Future Directions............................................411
References...................................................................................413
CHAPTER 19 What Does Addiction Medicine Expect from
Neuroscience? From Genes and Neurons to
Treatment Responses...........................................................419
Bernard Le Foil
1. Introduction.................................................................................420
2. Part 1: Understanding the NeuroCircuitry
of Addiction and Use the Power of Brain Stimulation..............421
3. Part 2: Understanding the Neurochemical Signature
of Addiction and Use this to Impact Clinical Care...................426
4. Part 3: Understanding the Role of Genetic Factors
and Use this to Impact Clinical Care.........................................430
4.1. Predicting Response to Alcohol Pharmacotherapy............430
4.2. Predicting Response to Tobacco Pharmacotherapy...........432
5. Conclusion and Future Directions..............................................435
Acknowledgment........................................................................435
References...................................................................................435
Index.......................................................................................................................449
Other volumes in PROGRESS IN BRAIN RESEARCH..............................................459
|
| any_adam_object | 1 |
| author2 | Ekhtiari, Hamed 1978- Paulus, Martin P. 1961- |
| author2_role | edt edt |
| author2_variant | h e he m p p mp mpp |
| author_GND | (DE-588)1103144065 (DE-588)1084786982 |
| author_facet | Ekhtiari, Hamed 1978- Paulus, Martin P. 1961- |
| building | Verbundindex |
| bvnumber | BV043593032 |
| ctrlnum | (OCoLC)951551737 (DE-599)GBV847038289 |
| edition | First edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01849nam a2200337 cb4500</leader><controlfield tag="001">BV043593032</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">160609s2016 a||| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">847038289</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780444635457</subfield><subfield code="c">hbk.</subfield><subfield code="9">978-0-444-63545-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0444635459</subfield><subfield code="c">hbk.</subfield><subfield code="9">0-444-63545-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)951551737</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBV847038289</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neuroscience for addiction medicine</subfield><subfield code="b">from prevention to rehabilitation - constructs and drugs</subfield><subfield code="c">edited by Hamed Ekhtiari (Neurocognitive Laboratory, Iranian National Center for Addiction Studies, INCAS ; Research Center for Molecular and Cellular Imaging, RCMCI, Tehran University of Medical Sciences, and Translational Neuroscience Program, Institute for Cognitive Science Studies, ICSS, Tehran, Iran), Martin Paulus (Laureate Institute for Brain Research, LIBR, Tulsa, OK, United States)</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">First edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam ; Boston ; Heidelberg ; London ; New York ; Oxford ; Paris ; San Diego ; San Francisco ; Singapore ; Sydney ; Tokyo</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xx, 357 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">24 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Progress in brain research</subfield><subfield code="v">volume 223</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ekhtiari, Hamed</subfield><subfield code="d">1978-</subfield><subfield code="0">(DE-588)1103144065</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paulus, Martin P.</subfield><subfield code="d">1961-</subfield><subfield code="0">(DE-588)1084786982</subfield><subfield code="4">edt</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Progress in brain research</subfield><subfield code="v">volume 223</subfield><subfield code="w">(DE-604)BV008000363</subfield><subfield code="9">223</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029007373&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029007373</subfield></datafield></record></collection> |
| id | DE-604.BV043593032 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:30:29Z |
| institution | BVB |
| isbn | 9780444635457 0444635459 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029007373 |
| oclc_num | 951551737 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | xx, 357 Seiten Illustrationen 24 cm |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Elsevier |
| record_format | marc |
| series | Progress in brain research |
| series2 | Progress in brain research |
| spelling | Neuroscience for addiction medicine from prevention to rehabilitation - constructs and drugs edited by Hamed Ekhtiari (Neurocognitive Laboratory, Iranian National Center for Addiction Studies, INCAS ; Research Center for Molecular and Cellular Imaging, RCMCI, Tehran University of Medical Sciences, and Translational Neuroscience Program, Institute for Cognitive Science Studies, ICSS, Tehran, Iran), Martin Paulus (Laureate Institute for Brain Research, LIBR, Tulsa, OK, United States) First edition Amsterdam ; Boston ; Heidelberg ; London ; New York ; Oxford ; Paris ; San Diego ; San Francisco ; Singapore ; Sydney ; Tokyo Elsevier 2016 xx, 357 Seiten Illustrationen 24 cm txt rdacontent n rdamedia nc rdacarrier Progress in brain research volume 223 Ekhtiari, Hamed 1978- (DE-588)1103144065 edt Paulus, Martin P. 1961- (DE-588)1084786982 edt Progress in brain research volume 223 (DE-604)BV008000363 223 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029007373&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Neuroscience for addiction medicine from prevention to rehabilitation - constructs and drugs Progress in brain research |
| title | Neuroscience for addiction medicine from prevention to rehabilitation - constructs and drugs |
| title_auth | Neuroscience for addiction medicine from prevention to rehabilitation - constructs and drugs |
| title_exact_search | Neuroscience for addiction medicine from prevention to rehabilitation - constructs and drugs |
| title_full | Neuroscience for addiction medicine from prevention to rehabilitation - constructs and drugs edited by Hamed Ekhtiari (Neurocognitive Laboratory, Iranian National Center for Addiction Studies, INCAS ; Research Center for Molecular and Cellular Imaging, RCMCI, Tehran University of Medical Sciences, and Translational Neuroscience Program, Institute for Cognitive Science Studies, ICSS, Tehran, Iran), Martin Paulus (Laureate Institute for Brain Research, LIBR, Tulsa, OK, United States) |
| title_fullStr | Neuroscience for addiction medicine from prevention to rehabilitation - constructs and drugs edited by Hamed Ekhtiari (Neurocognitive Laboratory, Iranian National Center for Addiction Studies, INCAS ; Research Center for Molecular and Cellular Imaging, RCMCI, Tehran University of Medical Sciences, and Translational Neuroscience Program, Institute for Cognitive Science Studies, ICSS, Tehran, Iran), Martin Paulus (Laureate Institute for Brain Research, LIBR, Tulsa, OK, United States) |
| title_full_unstemmed | Neuroscience for addiction medicine from prevention to rehabilitation - constructs and drugs edited by Hamed Ekhtiari (Neurocognitive Laboratory, Iranian National Center for Addiction Studies, INCAS ; Research Center for Molecular and Cellular Imaging, RCMCI, Tehran University of Medical Sciences, and Translational Neuroscience Program, Institute for Cognitive Science Studies, ICSS, Tehran, Iran), Martin Paulus (Laureate Institute for Brain Research, LIBR, Tulsa, OK, United States) |
| title_short | Neuroscience for addiction medicine |
| title_sort | neuroscience for addiction medicine from prevention to rehabilitation constructs and drugs |
| title_sub | from prevention to rehabilitation - constructs and drugs |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029007373&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV008000363 |
| work_keys_str_mv | AT ekhtiarihamed neuroscienceforaddictionmedicinefrompreventiontorehabilitationconstructsanddrugs AT paulusmartinp neuroscienceforaddictionmedicinefrompreventiontorehabilitationconstructsanddrugs |